OncoMatch/Clinical Trials/NCT07297979
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Is NCT07297979 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Xaluritamig for ewing sarcoma.
Treatment: Xaluritamig — The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Biomarker criteria
Required: EWSR1 translocation with an E26 transformation-specific (ETS) family gene (e.g., FLI1, ERG)
molecular evidence of an EWSR1 translocation with an E26 transformation-specific (ETS) family gene, eg, FLI1, ETS-related gene [ERG]) via next generation sequencing (based on local testing)
Prior therapy
Must have received: chemotherapy
Relapsed or refractory EWS following at least 1 line of chemotherapy (including treatment with an anthracycline and at least 1 alkylating agent)
Must have received: anthracycline
including treatment with an anthracycline
Must have received: alkylating agent
including treatment with ... at least 1 alkylating agent
Lab requirements
Blood counts
ANC ≥ 1.0 x 10^9/L (no short-acting growth factor within 7 days, no long-acting within 14 days); Platelets ≥ 75 x 10^9/L (no platelet transfusion within 7 days, no platelet stimulating agent within 14 days)
Kidney function
eGFR (MDRD) ≥ 30 mL/min/1.73 m^2 for ≥ 18 years; eGFR (Schwartz 2009) ≥ 30 mL/min/1.73 m^2 for < 18 years
Liver function
AST and ALT ≤ 3 x ULN (or ≤ 5 x ULN for participants with liver metastases); Total bilirubin ≤ 1.5 x ULN (unless related to Gilbert's or Meulengracht disease)
Cardiac function
Left ventricular ejection fraction ≥ 50%. If not measurable, left ventricular fractional shortening ≥ 28%
Adequate organ function, defined as follows: Hematological function: ANC ≥ 1.0 x 10^9/L (no short-acting growth factor within 7 days, no long-acting within 14 days); Platelet count ≥ 75 x 10^9/L (no platelet transfusion within 7 days, no platelet stimulating agent within 14 days). Renal function: eGFR (MDRD) ≥ 30 mL/min/1.73 m^2 for ≥ 18 years; eGFR (Schwartz 2009) ≥ 30 mL/min/1.73 m^2 for < 18 years. Hepatic function: AST and ALT ≤ 3 x ULN (or ≤ 5 x ULN for participants with liver metastases); Total bilirubin ≤ 1.5 x ULN (unless related to Gilbert's or Meulengracht disease). Pulmonary function: Baseline oxygen saturation > 92% in room air at rest and no oxygen supplementation. Cardiac function: Left ventricular ejection fraction ≥ 50%. If not measurable, left ventricular fractional shortening ≥ 28%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Los Angeles · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify